Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY

v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020   100,016,559    
Beginning balance at Dec. 31, 2020 $ 36,216 $ 10 $ 243,484 $ (207,278)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock upon exercise of stock options (in shares)   2,112,373    
Issuance of common stock upon exercise of stock options 30   30  
Vesting of early exercised stock options 24   24  
Repurchase of unvested restricted common stock (in shares)   (87,768)    
Issuance of Series D convertible preferred stock upon exercise of warrants (in shares)   2,020,034    
Issuance of Series D convertible preferred stock upon exercise of warrants 20,877   20,877  
Stock-based compensation 1,555   1,555  
Net income (loss) (16,165)     (16,165)
Ending balance (in shares) at Mar. 31, 2021   104,061,198    
Ending balance at Mar. 31, 2021 42,537 $ 10 265,970 (223,443)
Beginning balance (in shares) at Dec. 31, 2020   100,016,559    
Beginning balance at Dec. 31, 2020 36,216 $ 10 243,484 (207,278)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) (30,468)      
Ending balance (in shares) at Jun. 30, 2021   103,995,529    
Ending balance at Jun. 30, 2021 30,620 $ 10 268,356 (237,746)
Beginning balance (in shares) at Mar. 31, 2021   104,061,198    
Beginning balance at Mar. 31, 2021 42,537 $ 10 265,970 (223,443)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock upon exercise of stock options (in shares)   9,442    
Issuance of common stock upon exercise of stock options 4   4  
Vesting of early exercised stock options 29   29  
Repurchase of unvested restricted common stock (in shares)   (75,111)    
Stock-based compensation 2,353   2,353  
Net income (loss) (14,303)     (14,303)
Ending balance (in shares) at Jun. 30, 2021   103,995,529    
Ending balance at Jun. 30, 2021 30,620 $ 10 268,356 (237,746)
Beginning balance (in shares) at Jan. 02, 2022   152,272,287    
Beginning balance at Jan. 02, 2022 326,117 $ 15 659,254 (333,152)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock upon exercise of stock options (in shares)   91,910    
Issuance of common stock upon exercise of stock options 200   200  
Issuance of common stock upon exercise of common stock warrants (in shares)   4,126,466    
Issuance of common stock upon exercise of common stock warrants 47,452   47,452  
Vesting of early exercised stock options 42   42  
Vesting of restricted stock units (in shares)   34,941    
Repurchase of unvested restricted common stock (in shares)   (105,886)    
Stock-based compensation 4,536   4,536  
Net income (loss) 42,707     42,707
Ending balance (in shares) at Apr. 03, 2022   156,419,718    
Ending balance at Apr. 03, 2022 421,054 $ 15 711,484 (290,445)
Beginning balance (in shares) at Jan. 02, 2022   152,272,287    
Beginning balance at Jan. 02, 2022 $ 326,117 $ 15 659,254 (333,152)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock upon exercise of stock options (in shares) 138,717      
Net income (loss) $ 41,572      
Ending balance (in shares) at Jul. 03, 2022   156,678,690    
Ending balance at Jul. 03, 2022 428,740 $ 15 720,305 (291,580)
Beginning balance (in shares) at Apr. 03, 2022   156,419,718    
Beginning balance at Apr. 03, 2022 421,054 $ 15 711,484 (290,445)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock upon exercise of stock options (in shares)   46,807    
Issuance of common stock upon exercise of stock options 77   77  
Issuance of common stock under employee stock purchase plan (in shares)   126,574    
Issuance of common stock under employee stock purchase plan 1,113   1,113  
Vesting of early exercised stock options 28   28  
Vesting of restricted stock units (in shares)   115,990    
Repurchase of unvested restricted common stock (in shares)   (30,399)    
Stock-based compensation 7,603   7,603  
Net income (loss) (1,135)     (1,135)
Ending balance (in shares) at Jul. 03, 2022   156,678,690    
Ending balance at Jul. 03, 2022 $ 428,740 $ 15 $ 720,305 $ (291,580)